Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Aug 23, 2016 (10 years ago)

Selegiline HCL Tablets USP 5mg

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Stason Pharmaceuticals is recalling Selegiline HCl tablets, USP 5mg 60 count bottle due to an out of specification result for dissolution of stability samples.

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Selegiline HCL Tablets USP 5mg, 60- count bottles, Rx only, Manufactured by: Stason Pharmaceuticals, Inc. Irvine, CA 92618 Distributed by: Libertas Pharma, Inc. Montgomery, AL 36117. NDC 51862-146-06

Affected NDC 51862-0146-06

Compare with the code on your package — it is the most precise check available.

Recalling firm
Stason Pharmaceuticals, Inc.
NDC code
51862-146-06
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1479-2016 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Stason Pharmaceuticals, Inc.

All 2016 recalls
Class III · Low risk

Mercaptopurine Tablets

Failed Dissolution Specifications: results slightly under spec at at 9-months.

Terminated Dissolution failure Stason Pharmaceuticals, Inc. NDC 69076-913-02 D-0367-2024

Other dissolution failure recalls from 2016

All dissolution failure recalls
Class II · Moderate risk

Flucanozole Tablets

Failed Dissolution Specifications; 18 month stability time point

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-146-30 D-0452-2017
Class II · Moderate risk

Flucanozole Tablets

Failed Dissolution Specifications; 18 month stability time point

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-145-12 D-0451-2017
Class II · Moderate risk

Flucanozole Tablets

Failed Dissolution Specifications; 18 month stability time point

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-144-30 D-0450-2017
Class II · Moderate risk

Flucanozole Tablets

Failed Dissolution Specifications; 18 month stability time point

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-143-30 D-0449-2017